53261-25-9

Basic information

• Product Name: diamminedichlorodihydroxyplatinum IV
• Synonyms: diamminedichlorodihydroxyplatinum IV
• CAS NO: 53261-25-9
• Molecular Formula: Cl₂H₈N₂O₂Pt
• Molecular Weight: 330.03
• Mol File: 53261-25-9.mol
• Article Data: 67

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 5990mmHg at 25°C
• CAS DataBase Reference: diamminedichlorodihydroxyplatinum IV(CAS DataBase Reference)
• NIST Chemistry Reference: diamminedichlorodihydroxyplatinum IV(53261-25-9)
• EPA Substance Registry System: diamminedichlorodihydroxyplatinum IV(53261-25-9)

Safety Data

• Hazardous Substances Data: 53261-25-9(Hazardous Substances Data)

Usage

InChI:InChI=1/2ClH.2H3N.2H2O.Pt/h2*1H;2*1H3;2*1H2;/q;;;;;;+4/p-4

Upstream product

• 26035-31-4 cisplatine 
• 7722-84-1 dihydrogen peroxide 
• 15663-27-1 cisplatin 
• 7732-18-5 water 
• 26035-31-4 transplatin 
• 7722-64-7 potassium permanganate 

Downstream Products

• 16893-05-3 cis-diaammineplatinum(IV) tetrachloride 
• 15663-27-1 cisplatin 
• 1613703-75-5 C₃₈H₃₆Cl₄N₄O₈Pt 

Relevant articles and documents

Tetravalent platinum complex containing BET inhibitor and application

The invention discloses a tetravalent platinum complex containing a BET inhibitor. The structure of the tetravalent platinum complex is as shown in a general formula I, wherein substituent groups are defined in the specification. The advantages of the tetravalent platinum complex are utilized, and the synergistic anti-tumor effect of the BET inhibitor and cis-platinum is exerted. The tetravalent platinum complex containing the BET inhibitor shows broad-spectrum and excellent in-vitro anti-tumor activity, the activity of the tetravalent platinum complex is obviously superior to that of cis-platinum, the BET inhibitor and the mixture of the cis-platinum and the BET inhibitor according to the ratio of 1: 1, and the tetravalent platinum complex has huge potential of being developed into a novel broad-spectrum anti-tumor drug.

Human serum albumin loaded tetravalent platinum nanoparticles and preparation method thereof

The invention relates to human serum albumin loaded tetravalent platinum nanoparticles and a preparation method thereof, the nanoparticles are formed by self-assembly of albumin and a tetravalent platinum drug modified with double aliphatic chains, the structural formula of the tetravalent platinum drug is as shown in formula I or formula II, and n and m are respectively and independently selected from integers of 1-15. The nanoparticles can respond to the environment in tumor cells to release platinum drugs, therefore effectively reduce the system toxicity, overcome the drug resistance of the tumor cells, and have the advantage of enhancing the killing effect on the tumor cells.

Tetravalent platinum complex containing artesunate as well as preparation method and application of tetravalent platinum complex

The invention discloses a tetravalent platinum complex containing artesunate. The structure of the tetravalent platinum complex is shown as a general formula I or II, wherein R is shown in the specification, and R1 is a branched chain or straight chain saturated C1-C20 alkyl group, or a branched chain or straight chain unsaturated C1-C20 alkyl group. The tetravalent platinum complex containing artesunate provided by the invention has an obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549, intestinal cancer HCT116, breast cancer MDA-MB-231 and cis-platinum drug-resistant lung cancer, the anti-tumor activity of part of compounds is obviously superior to that of cis-platinum, and the tetravalent platinum complex containing artesunate can be used as anti-tumor candidate drugs for deeper research.